Canakinumab in a subgroup of patients with COVID-19

In a subgroup of patients, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a hyperinflammatory response that leads to acute respiratory distress syndrome.1 SARS coronaviruses have been shown to trigger the inflammasome and the release of interleukin-1β (IL-1β).2

Read the full article here

Related Articles